Bifogade filer
Bonesupport Q1 2023 EN
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BONESUPPORT Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2023-04-27 08:00:00
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
- Net sales increased by 80 percent (66 percent at constant exchange rates) and amounted to SEK 119.7 million (66.3).
- The North America (NA) segment reported a sales growth of 109 percent (87 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 34 percent (32 percent at constant exchange rates).
- The gross margin amounted to 90.5 percent (90.5).
- Operating result before effects from the Group’s incentive programs amounted to SEK +4.6 million (-12.5). Reported operating result amounted to SEK +0.8 million (-16.5).
- Earnings per share, before and after dilution, were SEK +0.00 (-0.32).
"Strong sales growth driven by CERAMENT G in the US." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
The FDA has announced that the label extension application for CERAMENT G, to include open fracture/trauma, should be made within the 510(k) regulatory framework and not within the De Novo regulatory framework.
EVENTS AFTER THE REPORTING PERIOD
Nothing to report.